Oncolytic Virotherapy

https://www.dovepress.com/oncolytic-virotherapy-archive141

List of Papers (Total 33)

Current understanding of reovirus oncolysis mechanisms

Current understanding of reovirus oncolysis mechanisms Matthew B Phillips,1 Johnasha D Stuart,1 Roxana M Rodríguez Stewart,2 Jameson TL Berry,2 Bernardo A Mainou,2 Karl W Boehme1 1Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Atlanta, GA, USA; 2Department of Pediatrics, Emory University, Atlanta, GA, USA Abstract: Mammalian orthoreovirus...

Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer

Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer Tien V Nguyen,1,* Catherine M Crosby,2,* Gregory J Heller,3 Zachary I Mendel,3 Mary E Barry,1 Michael A Barry1,4,5 1Department of Internal Medicine, Division of Infectious Diseases, 2Virology and Gene Therapy Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, 3Postbaccalaureate Research...

Proof-of-principle that a decoy virus protects oncolytic measles virus against neutralizing antibodies

Proof-of-principle that a decoy virus protects oncolytic measles virus against neutralizing antibodies Chun Xu,1,2,* Annika Verena Goß,1,* Carmen Dorneburg,1 Klaus-Michael Debatin,1 Jiwu Wei,2 Christian Beltinger1 1Department of Pediatrics and Adolescent Medicine, Section of Experimental Pediatric Oncology, University Medical Center Ulm, Ulm, Germany; 2Jiangsu Key Laboratory of...

The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses

The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses Adrian Pelin,1,2 Jiahu Wang,2,3 John Bell,1,2 Fabrice Le Boeuf2 1Department of Biochemistry, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada; 2Ottawa Hospital Research Institute, Center for Cancer Therapeutics, Ottawa, ON, Canada; 3Genvira Biosciences, Ottawa...

Oncolytic virotherapy in upper gastrointestinal tract cancers

Oncolytic virotherapy in upper gastrointestinal tract cancers Raquel Yokoda,1 Bolni M Nagalo,1 Mansi Arora,1 Jan B Egan,1 James M Bogenberger,1 Thomas T DeLeon,1 Yumei Zhou,1 Daniel H Ahn,1 Mitesh J Borad1–3 1Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Scottsdale, AZ, 2Department of Molecular Medicine, Center for Individualized Medicine, Mayo Clinic...

Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect

Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect Raquel Yokoda,1 Bolni M Nagalo,1 Brent Vernon,2 Rahmi Oklu,3 Hassan Albadawi,3 Thomas T DeLeon,1 Yumei Zhou,1 Jan B Egan,1 Dan G Duda,4 Mitesh J Borad1 1Division of Hematology Oncology, Department of Medicine, Mayo Clinic, Scottsdale, 2Department of Biomedical Engineering, Arizona State University...

Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity

Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity Yoshihiro Hotta,1 Hideki Kasuya,2 Itzel Bustos,2 Yoshinori Naoe,2 Toru Ichinose,2 Maki Tanaka,3 Yasuhiro Kodera1 1Department of Surgery II, 2Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine, Nagoya, 3Takara Bio Inc., Otsu, Japan Background: HF10 is a...

Proinflammatory response induced by Newcastle disease virus in tumor and normal cells

Proinflammatory response induced by Newcastle disease virus in tumor and normal cells Teridah Ernala Ginting, Jeremiah Suryatenggara, Salomo Christian, George Mathew Division of Immunology, Mochtar Riady Institute for Nanotechnology and Medical Science Group, University of Pelita Harapan, Tangerang, Indonesia Purpose: To investigate the specific role of immune responses induced...

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma Hani M Babiker,1 Irbaz Bin Riaz,2 Muhammad Husnain,2 Mitesh J Borad3,4 1University of Arizona Cancer Center, 2Department of Internal Medicine, University of Arizona, Tucson, 3Division of Hematology-Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ, 4Department of Molecular Medicine, Center for...

Novel oncolytic viral therapies in patients with thoracic malignancies

Novel oncolytic viral therapies in patients with thoracic malignancies Zeeshan Ahmad, Robert A Kratzke Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA Abstract: Oncolytic virotherapy is the use of replication-competent viruses to treat malignancies. The potential of oncolytic virotherapy...

Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes

Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes Marlana Orloff Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA Abstract: On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US Food and Drug Administration approval for...

Oncolytic Seneca Valley Virus: past perspectives and future directions

Oncolytic Seneca Valley Virus: past perspectives and future directions Michael J Burke Department of Pediatrics, Division of Pediatric Oncology, Medical College of Wisconsin, MACC Fund Research Center, Milwaukee, WI, USA Abstract: Seneca Valley Virus isolate 001 (SVV-001) is an oncolytic RNA virus of the Picornaviridae family. It is also the first picornavirus discovered of the...

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances Guy R Simpson,1 Kate Relph,1 Kevin Harrington,2 Alan Melcher,3 Hardev Pandha1 1Department of Clinical and Experimental Medicine, Targeted Cancer Therapy, Faculty of Health and Medical Sciences, University of Surrey, Guildford, 2Targeted Therapy, The Institute of Cancer Research/The Royal...

Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art

Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art Rounak Nande,1 Candace M Howard,2 Pier Paolo Claudio,3,4 1Department of Biochemistry and Microbiology, Marshall University School of Medicine, Huntington, WV, 2Department of Radiology, University of Mississippi Medical Center, Jackson, MS, 3Department of BioMolecular Sciences...

Oncolytic virotherapy using herpes simplex virus: how far have we come?

Oncolytic virotherapy using herpes simplex virus: how far have we come? Nicolas AS Sokolowski,1 Helen Rizos,2 Russell J Diefenbach1 1Centre for Virus Research, Westmead Millennium Institute for Medical Research, The University of Sydney, 2Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW, Australia Abstract: Oncolytic...

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy Hiroshi Nakashima, Tran Nguyen, Ennio Antonio ChioccaDepartment of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USAAbstract: Histone deacetylase (HDAC) enzymes play a critical role in the epigenetic regulation of cellular functions and signaling pathways in many cancers. HDAC inhibitors (HDACi...

Targeting tumor vasculature through oncolytic virotherapy: recent advances

Targeting tumor vasculature through oncolytic virotherapy: recent advances Marcela Toro Bejarano, Jaime R Merchan Division of Hematology–Oncology, Department of Medicine, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA Abstract: The oncolytic virotherapy field has made significant advances in the last decade, with a rapidly...

Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy

Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy Boris Simovic, Scott R Walsh, Yonghong Wan Department of Pathology and Molecular Medicine, McMaster Immunology Research Centre, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada Abstract: Immunotherapy and oncolytic virotherapy have both shown anticancer...

Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology

Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology Manuel Ramírez,1 Javier García-Castro,2 Gustavo J Melen,1 África González-Murillo,1 Lidia Franco-Luzón1 1Oncohematología, Hospital Universitario Niño Jesús, 2Unidad de Biotecnología Celular, Instituto de Salud Carlos III, Madrid, Spain Abstract: Oncolytic...

Oncolytic Sendai virus-based virotherapy for cancer: recent advances

Oncolytic Sendai virus-based virotherapy for cancer: recent advances Kotaro Saga, Yasufumi Kaneda Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Osaka, Japan Abstract: Many drugs have been developed and optimized for the treatment of cancer; however, it is difficult to completely cure cancer with anticancer drugs alone. Therefore, the development...

Oncolytic virotherapy for human malignant mesothelioma: recent advances

Oncolytic virotherapy for human malignant mesothelioma: recent advances Nicolas Boisgerault,1–3 Carole Achard,1–3 Tiphaine Delaunay,1–3 Laurent Cellerin,4 Frédéric Tangy,5 Marc Grégoire,1–3 Jean-François Fonteneau1–31INSERM, UMR892, 2CNRS, UMR6299, Health Research Institute of the University of Nantes, 3University of Nantes, 4Nantes CHU Hospital, Department of Thoracic and...

Characterization of an oncolytic adenovirus vector constructed to target the cMet receptor

Characterization of an oncolytic adenovirus vector constructed to target the cMet receptor Hany I Sakr,1–3 David T Coleman,3,4 James A Cardelli,3,4 J Michael Mathis,2,3,5 1Department of Cellular Biology and Anatomy, 2Gene Therapy Program, 3Feist-Weiller Cancer Center, 4Department of Microbiology and Immunology, LSU Health Shreveport, Shreveport, 5Department of Comparative...

On the potential of oncolytic virotherapy for the treatment of canine cancers

On the potential of oncolytic virotherapy for the treatment of canine cancers Amy L MacNeill Department of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA Abstract: Over 6 million dogs are diagnosed with cancer in the USA each year. Treatment options for many of these patients are...

Oncolytic virotherapy for head and neck cancer: current research and future developments

Oncolytic virotherapy for head and neck cancer: current research and future developments Akshiv Malhotra,1 Arun Sendilnathan,1 Matthew O Old,2 Trisha M Wise-Draper11Division of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, 2Department of Otolaryngology-Head and Neck Surgery, Ohio State University, Columbus, OH, USAAbstract: Head and...

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594) Caroline J Breitbach,1 John C Bell,2,3 Tae-Ho Hwang,1 David H Kirn,1 James Burke1 1SillaJen Inc, Seoul, South Korea; 2Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada; 3Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa...